文献速递骨质疏松与代谢性骨病

库欣综合征患者骨密度测量显著不足:基于美国保险理赔数据库的全国性研究

Notable lacking of bone mineral density measurement in cushing syndrome: a nationwide study based on the US insurance claim database.
PubMed 文献 · Osteoporos Int · 2025-03-18

该回顾性研究基于美国PearlDiver患者记录数据库(2010-2020年),纳入53,101例库欣综合征患者,排除既往骨质疏松诊断者。仅6.40%的患者在诊断后两年内接受骨密度检测,女性检测率7.85%显著高于男性2.58%(p<0.001)。作者认为尽管有指南推荐,骨密度筛查依从性仍严重不足,尤其在高风险人群中。

要点

  • 53,101例库欣综合征患者中仅6.40%在诊断后两年内接受骨密度检测。
  • 女性检测率7.85% vs 男性2.58%(p<0.001),接受检测者平均年龄62.79岁 vs 未检测者65.21岁(p<0.001)。
  • 接受检测者中12.56%被诊断为骨质疏松,年龄较大和吸烟显著增加诊断 odds。

核心结论

  • 尽管有指南推荐,仅6.40%的库欣综合征患者接受了骨密度筛查;在接受筛查者中12.56%被诊断为骨质疏松。
  • 作者认为这些发现凸显了提高筛查指南依从性的必要性,尤其针对高风险人群,以更好地管理和预防库欣综合征患者的骨质疏松。

研究设计与样本

  • 回顾性研究,使用PearlDiver患者记录数据库(2010-2020年)数据。
  • 纳入诊断为库欣综合征并接受骨密度检测的患者,排除既往骨质疏松诊断者。
  • 分析患者人口学特征、合并症和结局,使用t检验、卡方检验和逻辑回归,显著性设定为p<0.001。

主要发现

  • 53,101例库欣综合征患者中仅6.40%在诊断后两年内接受骨密度检测。
  • 女性检测率7.85% vs 男性2.58%(p<0.001),接受检测者平均年龄62.79岁 vs 未检测者65.21岁(p<0.001)。
  • 中西部区域检测率最高为7.1%,商业保险患者检测频率最高为7.5%。
  • 男性(OR=0.31;p<0.001)、年龄较大(OR=0.96;p<0.001)和较高Elixhauser合并症指数(ECI)评分(OR=0.89;p<0.001)与骨密度检测减少相关;肥胖(OR=1.51;p<0.001)和慢性肾脏病(OR=1.38;p<0.001)增加检测可能性。
  • 接受检测者中12.56%被诊断为骨质疏松,年龄较大和吸烟显著增加诊断 odds。

关键数值与推荐

  • 原文未报告具体的骨密度检测指南推荐条款或阈值。

临床怎么用

  • 原文未据此给出具体临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: This study examined the underuse of bone mineral density (BMD) testing in Cushing's syndrome patients, using a US insurance claims database. Despite osteoporosis risks, only 6.40% of 53,101 patients received BMD testing. The study underscores significant care gaps, particularly among males and older adults, necessitating improved screening efforts. BACKGROUND: Cushing syndrome (CS) is caused by long-term exposure to elevated glucocorticoid levels, primarily due to chronic steroid use, though it can also result from pituitary tumors. This condition leads to significant bone mineral density (BMD) loss and a heightened risk of osteoporosis. Despite guidelines for BMD testing in at-risk patients, osteoporosis has remained underdiagnosed in CS. The prevalence of BMD measurement in this group in the US continues to be unknown, indicating a gap in care. METHODS: We conducted a retrospective study using data from the PearlDiver Patient Records Database (2010-2020). Patients diagnosed with Cushing's syndrome who underwent BMD testing were included, while those with prior osteoporosis diagnoses were excluded. We analyzed patient demographics, comorbidities, and outcomes using t-tests, chi-squared tests, and logistic regression with significance set at p < 0.001. RESULTS: Among 53,101 identified Cushing's syndrome patients, only 6.40% underwent bone mineral density (BMD) testing within two years of diagnosis. Females were significantly more likely to be tested (7.85% vs. 2.58%; p < 0.001), and those tested were younger (mean age: 62.79 vs. 65.21 years; p < 0.001). The Midwest region had the highest testing rate at 7.1%, and patients with commercial insurance had the highest testing frequency at 7.5%. Factors associated with reduced BMD testing included male gender (OR = 0.31; p < 0.001), older age (OR = 0.96; p < 0.001), and higher Elixhauser Comorbidity Index (ECI) scores (OR = 0.89; p < 0.001). Conversely, obesity (OR = 1.51; p < 0.001) and chronic kidney disease (OR = 1.38; p < 0.001) increased the likelihood of testing. Among those tested, 12.56% were diagnosed with osteoporosis, with older age and tobacco use significantly increasing the odds of diagnosis. CONCLUSION: Despite guideline recommendations, only 6.40% of patients with Cushing's syndrome underwent BMD screening. Among those screened, 12.56% were diagnosed with osteoporosis.. These findings highlight the need for improved adherence to screening guidelines, particularly for high-risk populations, to better manage and prevent osteoporosis in Cushing's syndrome patients.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Ghaseminejad-Raeini A, Hoveidaei AH, Zarepour F, et al. Notable lacking of bone mineral density measurement in cushing syndrome: a nationwide study based on the US insurance claim database. Osteoporos Int. 2025. PMID: 40100349. doi:10.1007/s00198-025-07418-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。